|
Dr. Uprichard brings to EPIX extensive experience in the cardiovascular area as well as a unique combination of scientific and business expertise, encompassing both drug discovery and development, as well as licensing and acquisitions. Dr. Uprichard most recently was Chief Operating Officer of ArQule, Inc., where he initiated a strategy that helped transform ArQule from a chemistry platform company to a drug discovery and development organization. Prior to joining ArQule, he was Chief Operating Officer of Curis, Inc. Dr. Uprichard spent 11 years with Parke-Davis Pharmaceutical research (a division of Warner-Lambert) culminating in his role as Vice President, Drug Development, with responsibility for cardiovascular therapeutics from pre-clinical development through commercialization. Dr. Uprichard holds MB, ChB and MD degrees from the University of Edinburgh, Scotland, and is a Fellow of both the Royal College of Physicians of the UK and the American College of Physicians. | 